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Background: The antiretroviral nevirapine is associated with hypersensitivity reactions in 6-10% of patients, including hepatotoxicity, maculopapular exanthema, Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).  
Objective: To undertake a genome-wide association study (GWAS) to identify genetic predisposing factors for the different clinical phenotypes associated with nevirapine hypersensitivity.
Methods:  A GWAS was undertaken in a discovery cohort of 151 nevirapine-hypersensitive and 182 tolerant, HIV-infected Malawian adults.  Replication of signals was determined in a cohort of 116 cases and 68 controls obtained from Malawi, Uganda and Mozambique.  Interaction with ERAP genes was determined in patients positive for HLA-C*04:01.  In silico docking studies were also performed for HLA-C*04:01.
Results: Fifteen SNPs demonstrated nominal significance (p<1x10-5) with one or more of the hypersensitivity phenotypes.  The most promising signal was seen in SJS/TEN where rs5010528 (HLA-C locus) approached genome-wide significance (p<8.5x10-8) and was below HLA-wide significance (p<2.5x10-4) in the meta-analysis of discovery and replication cohorts (OR 4.84 (95% CI 2.71-8.61)).  rs5010528 is a strong proxy for HLA-C*04:01 carriage: in silico docking showed two residues (33 and 123) in the B-pocket were the most likely nevirapine interactors.  There was no interaction between HLA-C*04:01 and ERAP1, but there is a potential protective effect with ERAP2 (p=0.019, OR 0.43 (95% CI 0.21-0.87)).
Conclusions: HLA-C*04:01 predisposes to nevirapine-induced SJS/TEN in sub-Saharan Africans, but not to other hypersensitivity phenotypes.  This is likely to be mediated via binding to the B-pocket of the HLA allele. Whether this risk is modulated by ERAP2 variants requires further study.  
INTRODUCTION
Nevirapine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for human immunodeficiency virus (HIV) ADDIN EN.CITE 1 infection is effective HYPERLINK \l "_ENREF_2" \o "Siegfried, 2006 #138"  ADDIN EN.CITE <EndNote><Cite><Author>Siegfried</Author><Year>2006</Year><RecNum>138</RecNum><DisplayText><style face="superscript">2</style></DisplayText><record><rec-number>138</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1340094433">138</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Siegfried, N. L.</author><author>Van Deventer, P. J.</author><author>Mahomed, F. A.</author><author>Rutherford, G. W.</author></authors></contributors><auth-address>UK Cochrane Centre, Summertown Pavilion, Middle Way, Oxford. UK, OX2 7LG. nsiegfried@cochrane.co.uk</auth-address><titles><title>Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults</title><secondary-title>Cochrane Database Syst Rev</secondary-title></titles><periodical><full-title>Cochrane Database Syst Rev</full-title></periodical><pages>CD004535</pages><number>2</number><edition>2006/04/21</edition><keywords><keyword>Acquired Immunodeficiency Syndrome/drug therapy</keyword><keyword>Adult</keyword><keyword>Anti-HIV Agents/*therapeutic use</keyword><keyword>Drug Therapy, Combination</keyword><keyword>Female</keyword><keyword>HIV Infections/*drug therapy</keyword><keyword>Hiv-1</keyword><keyword>Humans</keyword><keyword>Lamivudine/administration &amp; dosage</keyword><keyword>Male</keyword><keyword>Nevirapine/administration &amp; dosage</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Reverse Transcriptase Inhibitors/*therapeutic use</keyword><keyword>Stavudine/administration &amp; dosage</keyword></keywords><dates><year>2006</year></dates><isbn>1469-493X (Electronic)&#xD;1361-6137 (Linking)</isbn><accession-num>16625606</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/16625606</url></related-urls></urls><electronic-resource-num>10.1002/14651858.CD004535.pub2</electronic-resource-num><language>eng</language></record></Cite></EndNote>2 as part of combination antiretroviral therapy, but causes hypersensitivity in 6-10% of patients.  ADDIN EN.CITE ,   This can manifest in various ways, ranging from nevirapine-induced rash (NIR) (i.e. a maculopapular exanthem without any systemic manifestations), hypersensitivity syndrome (HSS) to severe blistering skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) ADDIN EN.CITE 5 (1-2 per 1000 exposed individuals HYPERLINK \l "_ENREF_6" \o "Mittmann, 2012 #137"  ADDIN EN.CITE <EndNote><Cite><Author>Mittmann</Author><Year>2012</Year><RecNum>137</RecNum><DisplayText><style face="superscript">6</style></DisplayText><record><rec-number>137</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1340092507">137</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Mittmann, N.</author><author>Knowles, S. R.</author><author>Koo, M.</author><author>Shear, N. H.</author><author>Rachlis, A.</author><author>Rourke, S. B.</author></authors></contributors><auth-address>HOPE Research Centre, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.</auth-address><titles><title>Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study</title><secondary-title>Am J Clin Dermatol</secondary-title></titles><periodical><full-title>Am J Clin Dermatol</full-title></periodical><pages>49-54</pages><volume>13</volume><number>1</number><edition>2011/12/08</edition><keywords><keyword>Adult</keyword><keyword>Epidermal Necrolysis, Toxic/*epidemiology/etiology</keyword><keyword>Female</keyword><keyword>HIV Infections/complications/*epidemiology</keyword><keyword>Humans</keyword><keyword>Incidence</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Ontario/epidemiology</keyword><keyword>Retrospective Studies</keyword><keyword>Stevens-Johnson Syndrome/*epidemiology/etiology</keyword></keywords><dates><year>2012</year><pub-dates><date>Feb 1</date></pub-dates></dates><isbn>1175-0561 (Print)&#xD;1175-0561 (Linking)</isbn><accession-num>22145749</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/22145749</url></related-urls></urls><electronic-resource-num>10.2165/11593240-000000000-00000</electronic-resource-num><language>eng</language></record></Cite></EndNote>6).  Extra-cutaneous involvement typically manifests as hepatotoxicity.  ADDIN EN.CITE 7  

Identification of the genetic risk factors for nevirapine hypersensitivity has focused on candidate gene approaches.  nevirapine is primarily metabolised by the hepatic cytochrome P450s 2B6 (CYP2B6) and 3A4 (CYP3A4). HYPERLINK \l "_ENREF_8" \o "Riska, 1999 #18"  ADDIN EN.CITE <EndNote><Cite><Author>Riska</Author><Year>1999</Year><RecNum>18</RecNum><DisplayText><style face="superscript">8</style></DisplayText><record><rec-number>18</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1232011619">18</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Riska, P.</author><author>Lamson, M.</author><author>MacGregor, T.</author><author>Sabo, J.</author><author>Hattox, S.</author><author>Pav, J.</author><author>Keirns, J.</author></authors></contributors><auth-address>Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut 06877, USA. priska@rdg.boehringer-ingelheim.com</auth-address><titles><title>Disposition and biotransformation of the antiretroviral drug nevirapine in humans</title><secondary-title>Drug Metab Dispos</secondary-title></titles><periodical><full-title>Drug Metab Dispos</full-title></periodical><pages>895-901</pages><volume>27</volume><number>8</number><edition>1999/07/27</edition><keywords><keyword>Adult</keyword><keyword>Anti-HIV Agents/blood/*pharmacokinetics/urine</keyword><keyword>Biotransformation</keyword><keyword>Chromatography, High Pressure Liquid</keyword><keyword>Feces/chemistry</keyword><keyword>Half-Life</keyword><keyword>Humans</keyword><keyword>Hydrolysis</keyword><keyword>Male</keyword><keyword>Mass Spectrometry</keyword><keyword>Nevirapine/blood/*pharmacokinetics/urine</keyword><keyword>Spectrophotometry, Ultraviolet</keyword><keyword>Tissue Distribution</keyword></keywords><dates><year>1999</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>0090-9556 (Print)</isbn><accession-num>10421616</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=10421616</url></related-urls></urls><language>eng</language></record></Cite></EndNote>8 The exon 4 variant in CYP2B6 (c.516G>T), which encodes a non-synonymous amino acid substitution (Gln172His) (rs3745274), leads to loss of function,  ADDIN EN.CITE ,  with the variant T allele resulting in higher nevirapine plasma concentrations in both Caucasian ADDIN EN.CITE 11 and Sub-Saharan ADDIN EN.CITE 12 adult patients.  The associations with CYP2B6 polymorphisms are rather confusing with the CYP2B6 c.516G>T SNP associated with nevirapine-induced cutaneous adverse events in black and white populations ADDIN EN.CITE 13 but not with nevirapine-induced hepatotoxicity. ADDIN EN.CITE 14 The associations with HLA alleles is even more complex with HLA-DRB1*01:01 (Caucasian ADDIN EN.CITE , , ), HLA-C*04 (Thai HYPERLINK \l "_ENREF_17" \o "Likanonsakul, 2009 #17"  ADDIN EN.CITE <EndNote><Cite><Author>Likanonsakul</Author><Year>2009</Year><RecNum>17</RecNum><DisplayText><style face="superscript">17</style></DisplayText><record><rec-number>17</rec-number><foreign-keys><key app="EN" db-id="s90rszvsmaavsce92ws5xf9q22v29000vts2" timestamp="1386601457">17</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Likanonsakul, S.</author><author>Rattanatham, T.</author><author>Feangvad, S.</author><author>Uttayamakul, S.</author><author>Prasithsirikul, W.</author><author>Tunthanathip, P.</author><author>Nakayama, E. E.</author><author>Shioda, T.</author></authors></contributors><auth-address>Bamrasnaradura Infectious Diseases Institute, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand. imvbi@health2.moph.go.th</auth-address><titles><title>HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients</title><secondary-title>AIDS Res Ther</secondary-title></titles><periodical><full-title>AIDS Res Ther</full-title></periodical><pages>22</pages><volume>6</volume><edition>2009/10/23</edition><dates><year>2009</year></dates><isbn>1742-6405 (Electronic)&#xD;1742-6405 (Linking)</isbn><accession-num>19845952</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/19845952</url></related-urls></urls><custom2>2774340</custom2><electronic-resource-num>1742-6405-6-22 [pii]&#xD;10.1186/1742-6405-6-22</electronic-resource-num><language>eng</language></record></Cite></EndNote>17, Chinese HYPERLINK \l "_ENREF_18" \o "Gao, 2011 #133"  ADDIN EN.CITE <EndNote><Cite><Author>Gao</Author><Year>2011</Year><RecNum>133</RecNum><DisplayText><style face="superscript">18</style></DisplayText><record><rec-number>133</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1334825503">133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gao, S.</author><author>Gui, X. E.</author><author>Liang, K.</author><author>Liu, Z.</author><author>Hu, J.</author><author>Dong, B.</author></authors></contributors><auth-address>1 Department of Infectious Diseases, Zhongnan Hospital of Wuhan University , Wuhan, Hubei, China .</auth-address><titles><title>HLA-Dependent Hypersensitivity Reaction to Nevirapine in Chinese Han HIV-Infected Patients</title><secondary-title>AIDS Res Hum Retroviruses</secondary-title></titles><periodical><full-title>AIDS Res Hum Retroviruses</full-title></periodical><edition>2011/09/10</edition><dates><year>2011</year><pub-dates><date>Oct 19</date></pub-dates></dates><isbn>1931-8405 (Electronic)&#xD;0889-2229 (Linking)</isbn><accession-num>21902584</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/21902584</url></related-urls></urls><electronic-resource-num>10.1089/AID.2011.0107</electronic-resource-num><language>Eng</language></record></Cite></EndNote>18 and Black ADDIN EN.CITE 13), HLA-C*08 (Japanese HYPERLINK \l "_ENREF_19" \o "Gatanaga, 2007 #122"  ADDIN EN.CITE <EndNote><Cite><Author>Gatanaga</Author><Year>2007</Year><RecNum>122</RecNum><DisplayText><style face="superscript">19</style></DisplayText><record><rec-number>122</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1300719861">122</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Gatanaga, H.</author><author>Yazaki, H.</author><author>Tanuma, J.</author><author>Honda, M.</author><author>Genka, I.</author><author>Teruya, K.</author><author>Tachikawa, N.</author><author>Kikuchi, Y.</author><author>Oka, S.</author></authors></contributors><titles><title>HLA-Cw8 primarily associated with hypersensitivity to nevirapine</title><secondary-title>AIDS</secondary-title></titles><periodical><full-title>AIDS</full-title></periodical><pages>264-5</pages><volume>21</volume><number>2</number><edition>2007/01/02</edition><keywords><keyword>Adult</keyword><keyword>Anti-HIV Agents/*adverse effects</keyword><keyword>Drug Hypersensitivity/*etiology</keyword><keyword>Female</keyword><keyword>Genetic Predisposition to Disease</keyword><keyword>HIV Infections/drug therapy</keyword><keyword>Hiv-1</keyword><keyword>HLA-C Antigens/*genetics</keyword><keyword>Humans</keyword><keyword>Male</keyword><keyword>Nevirapine/*adverse effects</keyword><keyword>Reverse Transcriptase Inhibitors/adverse effects</keyword></keywords><dates><year>2007</year><pub-dates><date>Jan 11</date></pub-dates></dates><isbn>0269-9370 (Print)&#xD;0269-9370 (Linking)</isbn><accession-num>17197830</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17197830</url></related-urls></urls><electronic-resource-num>10.1097/QAD.0b013e32801199d9&#xD;00002030-200701110-00029 [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>19) and HLA-B*35:05 (Thai ADDIN EN.CITE , ) acting as predisposing alleles for nevirapine hypersensitivity.  Our own previous study within a sub-set of patients from the Malawian HIV-population described in this paper identified an association between HLA-C*04:01 and nevirapine-induced SJS.  HYPERLINK \l "_ENREF_21" \o "Carr, 2013 #168"  ADDIN EN.CITE <EndNote><Cite><Author>Carr</Author><Year>2013</Year><RecNum>168</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1365426900">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carr, D. F.</author><author>Chaponda, M.</author><author>Jorgensen, A. L.</author><author>Castro, E. C.</author><author>van Oosterhout, J. J.</author><author>Khoo, S. H.</author><author>Lalloo, D. G.</author><author>Heyderman, R. S.</author><author>Alfirevic, A.</author><author>Pirmohamed, M.</author></authors></contributors><auth-address>Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.</auth-address><titles><title>Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population</title><secondary-title>Clin Infect Dis</secondary-title></titles><periodical><full-title>Clin Infect Dis</full-title></periodical><pages>1330-9</pages><volume>56</volume><number>9</number><edition>2013/01/31</edition><dates><year>2013</year><pub-dates><date>May</date></pub-dates></dates><isbn>1537-6591 (Electronic)&#xD;1058-4838 (Linking)</isbn><accession-num>23362284</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23362284</url></related-urls></urls><electronic-resource-num>10.1093/cid/cit021&#xD;cit021 [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>21






Antiretroviral-naive patients (n=1117) were prospectively recruited as previously described HYPERLINK \l "_ENREF_21" \o "Carr, 2013 #168"  ADDIN EN.CITE <EndNote><Cite><Author>Carr</Author><Year>2013</Year><RecNum>168</RecNum><DisplayText><style face="superscript">21</style></DisplayText><record><rec-number>168</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1365426900">168</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Carr, D. F.</author><author>Chaponda, M.</author><author>Jorgensen, A. L.</author><author>Castro, E. C.</author><author>van Oosterhout, J. J.</author><author>Khoo, S. H.</author><author>Lalloo, D. G.</author><author>Heyderman, R. S.</author><author>Alfirevic, A.</author><author>Pirmohamed, M.</author></authors></contributors><auth-address>Department of Molecular and Clinical Pharmacology, University of Liverpool, United Kingdom.</auth-address><titles><title>Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population</title><secondary-title>Clin Infect Dis</secondary-title></titles><periodical><full-title>Clin Infect Dis</full-title></periodical><pages>1330-9</pages><volume>56</volume><number>9</number><edition>2013/01/31</edition><dates><year>2013</year><pub-dates><date>May</date></pub-dates></dates><isbn>1537-6591 (Electronic)&#xD;1058-4838 (Linking)</isbn><accession-num>23362284</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23362284</url></related-urls></urls><electronic-resource-num>10.1093/cid/cit021&#xD;cit021 [pii]</electronic-resource-num><language>eng</language></record></Cite></EndNote>21 (Figure 1) from the Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi, between March 2007 and December 2008.  All were self-reported black-African, over the age of 16, and had no baseline jaundice.  CD4+ counts and liver function tests were monitored at 0, 2, 6, 10, 14, 18 and 22 weeks.  Fifty seven patients from this prospective cohort had nevirapine-induced hypersensitivity fulfilling the criteria of one or more of the following phenotypes:
	nevirapine-induced rash (NIR): widespread maculopapular exanthem with no systemic manifestations but which worsened on treatment continuation.
	Hypersensitivity Syndrome (HSS): widespread rash with systemic manifestations (i.e. fever, cough or abnormal liver function tests (LFTs)). This is also known as DRESS (drug reaction with eosinophilia and systemic symptoms).
	SJS: blistering eruption affecting <10% of body surface area with ≥2 mucous membranes involved.
	TEN: blistering rash affecting >30% of body surface area and ≥2 mucous membranes.  Patients with overlap syndrome had 10-30% of their body surface area affected.
	Drug-induced Liver Injury (DILI): jaundice and abnormal alanine aminotransferase (ALT).

In addition, a total of 149 cases of nevirapine-induced hypersensitivity were recruited prospectively from QECH separately from the study described above, and a further 28 were identified retrospectively from patient records at the same centre.  Out of a total of 234 hypersensitive cases, 159 where sufficient genomic DNA was available were included, along with 193/1060 of the nevirapine-treated age and gender-matched controls (352 in total), into the discovery genome-wide association study. Numbers of tolerant controls included were constrained by DNA quality and quantity.

Replication Cohort
We recruited a number of patients with nevirapine hypersensitivity, with different phenotypes, from a number of centres (table 1) to replicate our findings:  
	Thirty nevirapine hypersensitive patients and matched (age and gender) HIV-positive nevirapine-treated controls from Malawi.  All controls and 8 of the cases were from the original study but not included in the initial GWAS due to DNA quantity restraints.  The other 22 cases presenting with the hypersensitivity phenotype according to the above criteria were identified from the QECH after the conclusion of the initial recruitment phase (December 2008).
	Thirty-two nevirapine hypersensitive cases and age and gender-matched controls identified in Uganda from the DART study cohort. ADDIN EN.CITE 23  Cases were defined according to available patient records and subsequently categorised into the sub-phenotypes described above.
	Twenty-seven pregnant female patients with nevirapine-induced hepatotoxicity and 10 nevirapine-tolerant pregnant controls from Mozambique.  Cases were defined as previously stated, ADDIN EN.CITE 24 and included patients who discontinued nevirapine due to increased liver enzymes (grade 3/4).  Controls were excluded if ALT/AST levels exceeded the median value observed in the case cohort. 
	Twenty-seven female patients with nevirapine-induced SJS/TEN from Mozambique. HYPERLINK \l "_ENREF_25" \o "Ciccacci, 2013 #184"  ADDIN EN.CITE <EndNote><Cite><Author>Ciccacci</Author><Year>2013</Year><RecNum>184</RecNum><DisplayText><style face="superscript">25</style></DisplayText><record><rec-number>184</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1397567909">184</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Ciccacci, C.</author><author>Di Fusco, D.</author><author>Marazzi, M. C.</author><author>Zimba, I.</author><author>Erba, F.</author><author>Novelli, G.</author><author>Palombi, L.</author><author>Borgiani, P.</author><author>Liotta, G.</author></authors></contributors><auth-address>Department of Biomedicine and Prevention, Genetics Section, School of Medicine, University of Rome &quot;Tor Vergata&quot;, 00133, Rome, Italy.</auth-address><titles><title>Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study</title><secondary-title>Eur J Clin Pharmacol</secondary-title><alt-title>European journal of clinical pharmacology</alt-title></titles><periodical><full-title>Eur J Clin Pharmacol</full-title></periodical><pages>1909-16</pages><volume>69</volume><number>11</number><dates><year>2013</year><pub-dates><date>Nov</date></pub-dates></dates><isbn>1432-1041 (Electronic)&#xD;0031-6970 (Linking)</isbn><accession-num>23774940</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23774940</url></related-urls></urls><electronic-resource-num>10.1007/s00228-013-1549-x</electronic-resource-num></record></Cite></EndNote>25  In this instance SJS/TEN was defined as development of exanthema and blistering starting mainly on the trunk, involving ≥10% of body surface with mucosal involvement.
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Full ethics approval for the study was received from the Liverpool School of Tropical Medicine Research Ethics Committee (Liverpool, UK), the College of Medicine Research and Ethics Committee, University of Malawi (Blantyre, Malawi) and the Uganda National Council for Science and Technology. All patients gave their written informed consent and those who met the criteria for a case had nevirapine withdrawn in accordance with Malawian National Treatment Guidelines. Local ethics approval was obtained for the DART study as previously described  ADDIN EN.CITE 23 with subsequent ethics approval for a pharmacogenetic sub-study also obtained. ADDIN EN.CITE 26

DNA extraction
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Discovery cohort genotyping and sample QC
A total of 352 samples were genotyped for 1,048,713 variants using the HumanOmni1-Quad_v1 chip (Illumina). Variants were excluded from analysis if their minor allele frequency (MAF) was below 1%, the call rate was below 99% for a MAF between 1 and 3 percent, the call rate was below 98% for a MAF over 3%, or if Hardy-Weinberg expectations were not satisfied (p<10-04).
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Discovery Cohort Imputation
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Discovery cohort association analysis
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Replication cohort genotyping, quality control (QC) and association analysis
SNPs determined to have a nominally significant association with a nevirapine hypersensitivity phenotype (p<1x10-5) in the discovery cohort were subsequently typed in the replication cohort using either the Sequenom MassArray iPLEX platform (Sequenom Inc, San Diego CA) or custom TaqMan real-time PCR SNP genotyping assays (Life Technologies, Paisley, UK) according to the manufacturer’s protocols.  SNPs were excluded if they failed to meet the genotype QC thresholds as outlined for the discovery cohort or if assay design software parameters prohibited their inclusion.
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Imputation of HLA- allelotype and MHC locus
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HLA-C and ERAP gene-gene interactions 
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Targeted Sequencing of MHC region 
Sixteen genomic DNA samples from nevirapine-induced SJS/TEN and 16 age- and gender-matched tolerant controls were carried forward for MHC-targeted sequencing.  The methodology is detailed in the supplementary data.

Allelotyping 
HLA allelotyping was performed from raw FASTQ data files using Omixon Target v1.81 HLA Typing software and utilised HLA database version 3.15.0. (Omixon Ltd, Budapest, Hungary).

In silico docking 




A total of 333 samples (151 cases and 182 controls) out of 352 passed QC.  Of the 19 excluded samples, 9 failed heterozygosity checks (outliers by >3SD), 8 failed identity checks, and 2 failed call rate threshold. Multi-dimensional analysis for population stratification (Supplementary Figure 1) demonstrated no population outliers.  In total, 817,728 SNPs passed QC and were carried over for imputation with the 1000 genomes panel. Imputation produced a dataset of 14,218,511 variants. Cohort characteristics are shown in Table 1. We considered five nevirapine-induced hypersensitivity phenotypes for analysis: NIR, HSS, SJS/TEN, DILI (table 1) and also combined these different phenotypes into an overall hypersensitivity group.    

Univariate logistic regression analysis showed CD4+ cell count to be a statistically significant variable for NIR (p=0.016), SJS (p=0.003) and for all hypersensitivity cases (p = 2.5x10-6).  Therefore, we included  CD4+ cell count as a covariate in the SNP logistic regression model for these three phenotypes.  Multidimensional scaling (MDS) variables were not included as covariates in the logistic regression since the population stratification analysis suggested that the cohort was homogeneous and genomic control was unnecessary (Supplementary Figure 1). From the genome-wide logistic regression analyses, we identified 15 SNPs with p<1x10-5, with at least one of the five different phenotypes analysed (Figure 2; summarised in Table 2).  No variant reached genome-wide significance.

Replication cohort
Of the 15 SNPs considered for replication, one (rs150223496) could not be typed due to proximal sequence constraints of the Sequenom assay design process, and QC failure for TaqMan genotyping (HWE p-value >0.0001, call rate >90%).  Thus, 14 SNPs were carried forward for analysis. A total of 59 Malawian samples (30 cases and 29 controls) and 63 Ugandan samples (32 cases and 31 controls) passed QC (call rate >90%) as described in Table 1.  Due to sample constraints, SNP signals identified in the discovery cohort for the “All hypersensitivity” phenotype were not typed in the samples from Mozambique in the replication cohort.

For nevirapine-induced DILI (table 3), combining the discovery and replication cohorts for the SNP rs6139258 in the RNF24 locus strengthened the association (p=5.7x10-7, OR 13.62 (95% CI 4.90-37.84)) (Table 4).  A single SNP (rs5010528 in the HLA-C locus) showed an association with SJS/TEN in the replication cohort (38 cases, 59 controls) (p=0.006; OR = 5.12 (95% CI 1.60-16.42)).  Combining the discovery and replication cohorts strengthened the overall association which approached genome-wide significance (p=8.5x10-8, OR 4.84 (95% CI 2.71-8.61). No positive signals were identified for the ‘all hypersensitivity’ phenotype (62 cases, 59 controls).  

HLA-C allelotype imputation
Overall allelotype imputation from the SNP array data using HLA*IMP demonstrated 71.5% concordance with the HLA typing obtained for 116 of our patients using the sequenced-based methodology. However the ability of the imputation to correctly call HLA-C*04:01 alleles was 90%.
Within the 116 patients for which HLA-allelotyping and SNP array genotype data were available, HLA-C-04:01 allele carriage co-occurred with rs5010528 G allele in 112/116 cases (96.5%).  For the imputed HLA-allelotype data, C*04:01 co-occurred with rs5010528 G in 303/333 cases (91%). 

The initial discovery logistic regression analysis demonstrated two non-synonymous SNPs in the HLA-C locus associated with SJS/TEN which were in absolute LD with rs5010528 (Table 5).  The first SNP (rs146911342) encodes a valine to methionine amino acid substitution at residue 327 and the second (rs1050409) encodes an alanine to glutamic acid at residue 73 (close to the peptide binding domain) was also associated with SJS/TEN (p=4.1x10-6, OR 4.75 (95% CI2.45-9.23)). Both are key defining residues of the HLA-C*04 allelotypes as defined in the HLA-IMGT database ADDIN EN.CITE 34 and within the Malawian cohort (Figure 3).  Verification of either SNP in our discovery or replication cohorts via other genotyping methodologies was not possible due to sequence constraints in assay design (proximal nucleotide sequence for primer design was not sufficiently unique or contained a restrictive number of other genetic variants).

However, targeted sequencing of the HLA locus in 16 SJS/TEN and 16 tolerant controls (Table 5) suggested that both the imputed non-synonymous SNPs may be in absolute LD with the original discovery cohort signal SNP (rs5010528), again demonstrating a significant association with nevirapine-induced SJS-TEN. Allelotype inference from the targeted sequencing SNP data also confirmed that both non-synonymous SNPs were in 100% co-occurrence with HLA-C*04:01 (data not shown).  Our data do not show an association between any of the other HLA gene loci and other nevirapine-induced hypersensitivity phenotypes.

HLA-C*04:01 and ERAP1 and ERAP2 SNP interactions
Given the previously reported interactions between ERAP genes and HLA class I mediated diseases, in particular ankylosing spondylitis, ADDIN EN.CITE 35 we determined whether there was an interaction with the carriage of HLA-C*04:01 using the rs5010528 G-allele as a proxy SNP (Supplementary Table 1).  There was no significant association (p>0.05) between the ERAP1 variants and SJS/TEN risk in carriers of HLA-C*04:01.  However, both ERAP2 variants showed a nominal association with SJS/TEN risk (p=0.019, OR 0.43 (95% CI 0.21-0.87)) though this did not pass the Bonferroni threshold for multiple testing (p=0.0125).

In silico docking
In light of the association observed between nevirapine-induced SJS/TEN and a SNP (rs1050409) encoding an amino acid substitution at residue 73 of HLA-C (p.A73E), in silico docking was undertaken to determine the possible effect of the residue substitution on nevirapine binding. The data suggest that none of the predicted modes of nevirapine docking conformation interact with residue 73, which appears to be on the periphery of the peptide binding domain (Figure 3). The lowest scoring (predicted highest affinity) mode highlights an interaction between nevirapine and residues 33 and 123 in the B-pocket (Figure 3). In HLA-C*04:01, residues 33 and 123 are serine and phenylalanine respectively (Figure 3). The majority of other allelotypes do not possess these particular residues (with the exception of C*04:07 and C*14:02). Docking of the metabolite 12-hydroxy-nevirapine was also undertaken, since it also has been suggested as potentially responsible for nevirapine-induced adverse drug reactions HYPERLINK \l "_ENREF_36" \o "Sharma, 2013 #209"  ADDIN EN.CITE <EndNote><Cite><Author>Sharma</Author><Year>2013</Year><RecNum>209</RecNum><DisplayText><style face="superscript">36</style></DisplayText><record><rec-number>209</rec-number><foreign-keys><key app="EN" db-id="estrw05vtwaprzeeftl5fdfqztfzftsxftvw" timestamp="1434632508">209</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sharma, A. M.</author><author>Novalen, M.</author><author>Tanino, T.</author><author>Uetrecht, J. P.</author></authors></contributors><auth-address>Leslie Dan Faculty of Pharmacy, University of Toronto , Toronto, Ontario M5S 3M2, Canada.</auth-address><titles><title>12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash</title><secondary-title>Chem Res Toxicol</secondary-title><alt-title>Chemical research in toxicology</alt-title></titles><periodical><full-title>Chem Res Toxicol</full-title></periodical><pages>817-27</pages><volume>26</volume><number>5</number><keywords><keyword>Animals</keyword><keyword>Exanthema/*chemically induced/*metabolism/pathology</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Molecular Structure</keyword><keyword>Nevirapine/*adverse effects/*analogs &amp; derivatives/chemistry/metabolism</keyword><keyword>Rats</keyword><keyword>Rats, Inbred BN</keyword><keyword>Time Factors</keyword></keywords><dates><year>2013</year><pub-dates><date>May 20</date></pub-dates></dates><isbn>1520-5010 (Electronic)&#xD;0893-228X (Linking)</isbn><accession-num>23590230</accession-num><urls><related-urls><url>http://www.ncbi.nlm.nih.gov/pubmed/23590230</url></related-urls></urls><electronic-resource-num>10.1021/tx400098z</electronic-resource-num></record></Cite></EndNote>36 – these were in general agreement with those for nevirapine, in that docking seems to take place around the B-pocket (for example near residues 33 and 123), but with more variability in the different modes predicted than for nevirapine. None of the predicted modes interacted with residue 73 (data not shown). Taken together, the docking results suggest that binding of either nevirapine or 12-hydroxy-nevirapine around the centre of the peptide binding regions is likely to be important in the mechanism of the immune-mediated reaction.

DISCUSSION
The investigation of genetic factors predisposing to serious adverse drug reactions is challenging because of their rarity.  Despite this, we have assembled one of the largest cohorts of patients with clinically well-characterised nevirapine hypersensitivity, including SJS/TEN.  GWAS analysis of our Malawian discovery cohort (n=333) identified 15 polymorphisms having a suggestive association with nevirapine hypersensitivity (Table 2).  Subsequent analysis of these variants in our replication cohort suggested that three of the SNPs may be potential risk factors (Table 3): rs34213790 3' in the HLA-B gene locus with all hypersensitivity phenotypes; rs5010528 in the HLA-C gene locus with SJS/TEN, and rs6139258 in the RNF24 gene locus with DILI. The weakest of the above three association signals, SNP rs34213790, is unlikely to be an independent marker of nevirapine hypersensitivity in general, and its association may be due to a haplotype effect between HLA-C*04:01 (rs5010528; see below) and B allelotypes.
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In terms of clinical utility, rs5010528 appears to have little potential as a pre-emptive genetic test. Indeed, based on a prevalence of SJS/TEN in our prospective cohort of 1.07% and assuming a dominant mode of inheritance, the positive (PPV) and negative (NPV) predictive values were 2.8% and 42.4% respectively.  For the RNF24 variant (rs6139258) the PPV, based on a prevalence of DILI of 0.63%, is also very low (0.2%).

Only one previous GWAS investigating nevirapine hypersensitivity has been reported but in a smaller Thai population (72 cases, 77 controls). ADDIN EN.CITE 39  Patients had a wide variety of rashes with only 11 grade 4 cases (6.9%), which would be equivalent to our cases with SJS/TEN. The SNP rs9461684 in the HLA-C locus was significantly associated with nevirapine rash, but no HLA allelotype imputation or HLA-sequencing was carried out.  In our data, rs9461684 is in high linkage disequlibrium (LD) with our top SNP rs5010528 (D'=1.0, r2=0.972).  The discrepancy may be a result of the different LD patterns in the different ethnic groups studied, as well as the much lower numbers of patients with serious skin reactions in the Thai study.  

From the imputed SNP data of the discovery cohort and targeted resequencing data (Table 5), it is clear that rs5010528 is in LD with a functional non-synonymous SNP (rs1050409) that leads to a alanine to glutamic acid substitution at residue 73 which lies near to the peptide binding domain of the HLA-C protein. However, in silico modelling suggested that this residue does not interact with nevirapine in any docking conformation.  Two other residues of HLA-C*04:01 (33 and 123 in the model) appear to be the key interactors in the majority of the predicted modes of nevirapine docking (Figure 3) including the most favoured.  However, it should be noted, that this is a predictive model and further analysis of the HLA-C/nevirapine complex is needed to further elucidate the potential for docking.  The association signal at residue 73 (rs1050409) is likely to be a proxy for the 33 and 123 residues also present in HLA-C*04:01.  However, this work has provided the first evidence that nevirapine binds to the B-pocket of HLA-C*04:01.

ERAP gene variants interact in a protective manner in HLA-mediated diseases such as ankylosing spondylitis in individuals who carry the risk HLA alleles. ADDIN EN.CITE 35  ERAP1 and ERAP2 are enzymes involved in antigenic peptide precursor trimming prior to loading into HLA class I molecules (and may thus alter the peptidome) and may potentially also alter the expression of the risk HLA class I allele.  To our knowledge, this is one of the first examinations of whether there is interaction between drug-induced HLA disease and the ERAP genes.  We were however unable to detect an interaction between ERAP1 variants and HLA-C*04:01 in African patients with SJS/TEN.  However, a nominal association (p=0.019) was observed for both ERAP2 SNPs (Supplementary Table 1).  A limitation of our analysis is the small sample size, particularly given the much larger numbers which have been studied in ankylosing spondylitis.  Nevertheless, the possibility of an association with ERAP2 is intriguing, and needs further investigation not only with nevirapine-induced hypersensitivity, but also with other HLA-related adverse drug reactions.








Figure 1. Schematic representation of the source of both nevirapine-hypersensitive and tolerant patients for the GWAS discovery and replication cohorts.

Figure 2. Manhattan plots of association for logistic regression SNP analysis for the 5 defined nevirapine hypersensitivity phenotypes.  The phenotypes, all hypersensitivity, NIR and SJS/TEN show p-values from logistic regression incorporating CD4+ count as a covariate.  The dashed line indicates genome-wide significance (p=5x10-8).
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Table 1.  Non-genetic data for nevirapine-tolerant and hypersensitive patient cohorts included in both the main and replication analyses after sample exclusion based on genotyping QC criteria.
	Cases (Median (Range))	Controls (Median (Range))	Phenotype (n)
	 (n)	Age	Gender (F)	BMI	CD4+	(n)	Age	Gender (F)	BMI	CD4+	NIR	HSS	SJS/TEN	DILI
Discovery Cohort1	151	35 (17-69)	63%	20.5 (14.6-41.4)	235 (3-906)	182	35 (17-63)	60%	20.2 (13.7-36.4)	170 (2-677)	56	23	51	21
														
Replication Cohort														
Malawi3	30	36 (24-58)	48%	19.8 (13.1-26.8)	207 (15-560)	29	36 (24-56)	47%	19.9 (14.9-30.3)	145 (25-314)	13	3	92	62
Uganda	32	37 (24-62)	73%	21.1 (8.9-39.6)	73 (17-201)	31	37 (25-53)	71%	21.3 (11.5-35.6)	66 (11-196)	14	8	2	10
Mozambique (SJS/TEN)4	27	31 (21-52)	100%	22.8 (12.4-35.0)	467 (107-906)	8	31 (23-41)	100%	27.5 (26.1-35.0)	556 (244-682) 	-	-	27	-
Mozambique (DILI)	27	32 (23-43)	100%	23.7 (13.7-34.0)	324 (23-2305)	-	-	-	-	-	-	-	-	27
Combined	116	34 (21-62)	78%	21.7 (8.9-39.6)	198 (15-2305)	68	36 (23-56)	64%	20.9 (11.5-35.6)	102 (11-682)	27	10	38	42
														








Table 2.   Top SNPs identified in association with a nevirapine hypersensitivity phenotype within the main cohort analysis.    P-values and odds ratio were determined by logistic regression with CD4+ cell count as a covariate (except for HSS and DILI).  *Denotes SNP signal where replication in the replication cohort was not possible due to genotyping assay design constraints.

Phenotype	SNP	Chr	Position (GRCh37 .p13)	Ref Allele	Assoc Allele	Gene	Typed/ Imputed	Logistic regression
								p-value	OR (95%CI)

















Table 3 . Logistic regression analysis of candidate SNPs in the nevirapine hypersensitivity replication cohort. *Denotes SNP signal where replication in the replication cohort was not possible; # denotes SNPs within the association signal which are substituted from the discovery cohort SNP (high LD) due to genotyping assay design constraints and ~denotes SNPs which were not be typed in the Mozambique DILI cohort (case n=15). Mozambique individuals were also omitted from the “All hypersensitivity” analysis.    SNP associations below arbitrary statistical significance (p<0.1) are highlighted in bold. 

Phenotype	SNP	Chr	Position (GRCh37 .p13)	Genotyping Platform	Ref Allele	Assoc Allele	Gene	Logistic regression
								p-value	OR (95%CI)













































Table 5.  Association of nevirapine-induced SJS/TEN and imputed SNPs of the HLA-C locus from the main cohort and the targeted sequencing cohort.   The list comprises all SNPs with a p-value of <1x10-5 in the main cohort analysis. Statistical significance and OR (95%CI) for the targeted sequencing cohort is determined by logistic regression with CD4+ cell count as covariate.  *denotes SNP was imputed in the discovery cohort analysis but not detected and or called in the sequencing data
				GWAS (Discovery Cohort)	Targeted Sequencing Cohort
SNP	bp(GRCh37.p13)	A1/A2	Amino Acid Substitution		SJS/TENMAF (n=51)	ControlMAF (n=182)	p	OR (95% CI)	SJS/TENMAF (n=16)	ControlMAF (n=16)	p	OR (95% CI)	LD with rs5010528 (D')
													
rs146911342	31237779	C/T	p.V327M	Imputed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	1
rs41562714	31238538	G/C		Imputed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	1
rs1050409	31239501	G/T	p.A73E	Imputed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	1
rs41553018	31239742	G/C		Imputed	0.36	0.15	3.71x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	1
rs4361609	31240635	G/C		Imputed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	1
rs5010528	31241032	A/G		Typed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	0.34	0.13	0.013	34.14 (2.07-561.6)	-
rs58019823	31241215	A/G		Imputed	0.36	0.15	4.13x10-6	4.75 (2.45-9.23)	-	-	-	-	n/a
*rs2524087	31241294	C/G		Imputed	0.37	0.15	3.71x10-6	4.73 (2.45-9.14)	-	-	-	-	n/a
*rs59103503	31287944	G/T		Imputed	0.37	0.15	2.75x10-6	5.00 (2.55-9.80)	-	-	-	-	n/a
*rs77641320 (​http:​/​​/​www.ncbi.nlm.nih.gov​/​projects​/​SNP​/​snp_ref.cgi?rs=77641320​)	31298229	C/G		Imputed	0.35	0.14	1.64x10-6	5.53 (2.75-11.12)	-	-	-	-	n/a
*rs9468965	31300247	T/A		Imputed	0.44	0.19	2.24x10-6	4.61 (2.24-8.69)	-	-	-	-	n/a
*rs35364987	31309423	T/C		Imputed	0.49	0.27	8.01x10-6	3.76 (2.10-6.74)	-	-	-	-	n/a
*rs35435945	31311374	T/G		Imputed	0.49	0.27	9.83x10-6	3.72 (2.08-6.67)	-	-	-	-	n/a
*rs35278939	31319780	G/A		Imputed	0.47	0.23	8.01x10-6	4.04 (2.19-7.47)	-	-	-	-	n/a
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